HUYA Bioscience announces orphan drug Designation for HBI-8000 in Japan

▴ HUYA Bioscience announces orphan drug Designation for HBI-8000 in Japan
HBI-8000 for Monotherapy Adult T-cell Leukemia-Lymphoma ATL

HUYA Bioscience International, the leader in accelerating the global development of China's pharmaceutical innovations, announced today the Ministry of Health, Labour and Welfare (MHLW) granted HBI-8000 orphan drug designation (ODD) in Japan as monotherapy for relapsed or refractory Adult T-cell Leukemia-Lymphoma or (ATL). HBI-8000 already has ODD in Japan for peripheral T-cell lymphoma (PTCL).

ATL is caused by latent infection of the human t-cell leukaemia virus type 1 or HTLV-1 and is endemic in Japan with up to one million carriers and a disease incidence estimated at 0.05-0.10%. There are approximately 2,000 patients and as many as 700 - 1,000 deaths reported each year. It is primarily a disease of the elderly with poor prognosis, the three-year survival rate in aggressive ATL after chemotherapy is 25% and few effective treatment options other than allogeneic bone marrow transplantation and high dose chemotherapy in a subset of eligible patients.

"Effective treatment options for relapsed or refractory (R/R) aggressive ATL are very limited and the designation of ODD status recognizes the need for a new treatment for this difficult-to-manage disease, I hope that development of HBI-8000 could be accelerated with the ODD," said Dr. Kunihiro Tsukasaki, MD PhD, Principal Investigator of HBI-8000 clinical study & Professor, Department of Hematopoietic Tumor, Saitama Medical University, International Medical Center.

HBI-8000 is an epigenetic immunomodulator approved for the treatment of lymphoma and metastatic breast cancer in China. This oral agent targets class I histone deacetylase (HDAC) and suppresses the expression of the viral oncogene HTLV-I bZIP factor, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and the inflammasome in ATL cells. Furthermore, HBI-8000 may induce latent viral antigen expression making ATL cells more sensitive to immune cytotoxicity targeting viral antigens. This is a novel mechanism of action and does not overlap with currently available drugs. Recent clinical studies conducted by HUYABIO in Japan suggest clinical efficacy of HBI-8000 in this rare disease setting of R/R aggressive ATL.

"The orphan drug designation of HBI-8000 recognizes the potential of this agent to meet an important unmet medical need and ATL is a critical public health issue in Japan," said Dr. Mireille Gillings, CEO & Executive Chair of HUYABIO. "The designation is appropriate for this rare malignancy, which afflicts an elderly population with such devastating effects. We are now preparing an application to the PMDA for approval of HBI-8000 as monotherapy for the treatment for R/R ATL."

Tags : #HuyaBiosciences #OrphanDrugDesignation #HBI800 #MonotherapyforAdultTcellLeukemia #Lymphoma #LatestPharmaApprovalJapanNewsNov1 #LatestPharmaNewsUpdateNov1

About the Author

Team Medicircle

Related Stories

Loading Please wait...

Trending Now

Daily Covid-19 cases in US will hit six digits soon, warns expertsOctober 24, 2020
ICMR backed Covaxin could be ready by June 2021 ; Bharat BiotechOctober 24, 2020
Sewage signals early warning of coronavirus outbreaksOctober 24, 2020
U.S. sets single-day record for COVID-19 cases during new surgeOctober 24, 2020
Expert finds limited effectiveness of convalescent plasma for covid-19 patientsOctober 24, 2020
87 year old homeopathic doctor provides home visits to COVID-19 patients in Chandrapur district of MaharashtraOctober 24, 2020
Steroids boost survival of preterm babies in low-resource settings, new study findsOctober 24, 2020
Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic CancerOctober 24, 2020
FDA authorises restart of the COVID-19 AZD1222 vaccine US Phase III trialOctober 24, 2020
New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological CancersOctober 24, 2020
PMI Announces Medicago to Supply Up to 76 Million Doses of Its Plant-Derived COVID-19 Vaccine CandidateOctober 24, 2020
Gujarat records 1112 new cases of COVID-19 in last 24 hoursOctober 24, 2020
2377 COVID-19 patients recovered in Odisha in last 24 hoursOctober 24, 2020
Over 70 lakh people recovered from COVID-19 infection in country so farOctober 24, 2020
Health Minister Harsh Vardhan says next three months are crucial for country in fight against COVID-19October 24, 2020
Pfizer's Hospital Business section acquires Arixa Pharma October 24, 2020
India crosses the landmark of 10 crore total testsOctober 24, 2020
Bharat Biotech to conduct Phase 3 Trials Of Covaxin On 26,000 people across 25 sitesOctober 24, 2020
Catalent launches OptiGel DR, a delayed/enteric release Softgel October 24, 2020
Health Protection Campaign to be launched soon in ChhattisgarhOctober 24, 2020